RhoTM

lives impacted by Rho

Rho utilizes routinely captured x-rays to opportunistically identify patients at risk of low bone mineral density.
‍

Licensed by Health Canada

FDA De Novo Marketing Authorization

This product is protected by Patents US 12,186,092 B2, US 11,737,704 B2, CA 3,141,427 A1,
IL 3,162,11 B2. All rights reserved.

80% of people aged 50+ undergo an x-ray.

Clinical Risk Assessment

Fall Prevention

Lifestyle Modification

DXA Screening

Impacting care through AI-driven opportunistic screening.

Only

1 in 4

eligible women are currently screened for osteoporosis.

Up-to

50%

of men are never screened for osteoporosis.

RhoTM can utilize

80%

of imaging data captured during routine care.

Number of individuals with low BMD:

42 million

potential lives impacted.

Finally, AI designed to improve outcomes for the patients you serve delivered through a value-based care model.

Leverage Existing Data

Increase Screening Rates

Increase Revenue

Maximize DXA Capacity

Cloud or On-Premise

PACS Integration